We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
Read MoreHide Full Article
GE HealthCare (GEHC - Free Report) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.14, which beat the Zacks Consensus Estimate of $1.06 by 7.5%. Also, the bottom line improved 15.2% year over year.
GAAP EPS in the quarter was $1.02, up 22.9% from the year-ago level.
The company reported revenues of $4.86 billion, up 1% year over year on a reported as well as organic basis. The top line was on par with the Zacks Consensus Estimate. Total company orders increased 1% organically year over year. Excluding China, sales as well as orders grew in the mid-single digit percentage points.
The top line was driven by strength in the U.S. market across all segments. Moreover, strong procedure volumes drove robust growth for the Pharmaceutical Diagnostics segment. However, continued softness in the Chinese market partially offset the growth.
Segmental Details
Imaging
Revenues from this segment totaled $2.23 billion, flat year over year reportedly. Organically, revenues declined 1%.
Segment EBIT was $287 million, up 18% year over year.
Advanced Visualization Solutions
Revenues totaled $1.22 billion, flat year over year reportedly as well as organically.
Segment EBIT was $232 million, down 9% year over year.
Patient Care Solutions
Revenues amounted to $779 million, up 2% from the year-ago level, reportedly as well as organically.
Segment EBIT was $82 million, up 3% year over year.
Pharmaceutical Diagnostics
Revenues totaled $625 million, up 6% from the year-ago level. Organically, revenues improved 7%.
Segment EBIT was $193 million, up 30.9% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
Net income margin was 9.7%, up 190 basis points from the prior-year level, primarily due to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the third quarter was $1.04 billion compared with $1.05 billion a year ago.
Financial Position
GEHC exited the third quarter with cash, cash equivalents and investments of $3.57 billion compared with $2.02 billion in the previous quarter.
Total assets increased to $33.86 billion from $31.85 billion on a sequential basis.
2024 Guidance
GE HealthCare updated its earnings and organic revenue guidance for 2024.
The company has raised its guidance for adjusted EPS and now expects it to be in the range of $4.25-$4.35 (previously $4.20-$4.35), indicating growth of 8-11%. Revenues are now anticipated to be at the lower-end of the guided range of 1-2% organically due to softness in China. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.26 and $19.74 billion, respectively.
ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 19.2% year to date against the industry’s 6.1% growth.
Avanos, sporting a Zacks Rank of 1 at present, has an estimated growth rate of 31.2% for 2025. AVNS’ earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 5.7%.
Avanos’ shares have risen 5.3% year to date compared with the industry’s 5.1% growth.
Globus Medical, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 38.7% year to date compared with the industry’s 6.1% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
GE HealthCare (GEHC - Free Report) reported third-quarter 2024 adjusted earnings per share (EPS) of $1.14, which beat the Zacks Consensus Estimate of $1.06 by 7.5%. Also, the bottom line improved 15.2% year over year.
GAAP EPS in the quarter was $1.02, up 22.9% from the year-ago level.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
Revenue Details
The company reported revenues of $4.86 billion, up 1% year over year on a reported as well as organic basis. The top line was on par with the Zacks Consensus Estimate. Total company orders increased 1% organically year over year. Excluding China, sales as well as orders grew in the mid-single digit percentage points.
The top line was driven by strength in the U.S. market across all segments. Moreover, strong procedure volumes drove robust growth for the Pharmaceutical Diagnostics segment. However, continued softness in the Chinese market partially offset the growth.
Segmental Details
Imaging
Revenues from this segment totaled $2.23 billion, flat year over year reportedly. Organically, revenues declined 1%.
Segment EBIT was $287 million, up 18% year over year.
Advanced Visualization Solutions
Revenues totaled $1.22 billion, flat year over year reportedly as well as organically.
Segment EBIT was $232 million, down 9% year over year.
Patient Care Solutions
Revenues amounted to $779 million, up 2% from the year-ago level, reportedly as well as organically.
Segment EBIT was $82 million, up 3% year over year.
Pharmaceutical Diagnostics
Revenues totaled $625 million, up 6% from the year-ago level. Organically, revenues improved 7%.
Segment EBIT was $193 million, up 30.9% year over year.
GE HealthCare Technologies Inc. Price, Consensus and EPS Surprise
GE HealthCare Technologies Inc. price-consensus-eps-surprise-chart | GE HealthCare Technologies Inc. Quote
Margins
Net income margin was 9.7%, up 190 basis points from the prior-year level, primarily due to benefits from productivity and pricing.
Cumulative cash flow from operating activities at the end of the third quarter was $1.04 billion compared with $1.05 billion a year ago.
Financial Position
GEHC exited the third quarter with cash, cash equivalents and investments of $3.57 billion compared with $2.02 billion in the previous quarter.
Total assets increased to $33.86 billion from $31.85 billion on a sequential basis.
2024 Guidance
GE HealthCare updated its earnings and organic revenue guidance for 2024.
The company has raised its guidance for adjusted EPS and now expects it to be in the range of $4.25-$4.35 (previously $4.20-$4.35), indicating growth of 8-11%. Revenues are now anticipated to be at the lower-end of the guided range of 1-2% organically due to softness in China. The Zacks Consensus Estimate for EPS and revenues is pegged at $4.26 and $19.74 billion, respectively.
Zacks Rank and Stocks to Consider
GEHC carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the same medical industry are AngioDynamics (ANGO - Free Report) , Avanos Medical (AVNS - Free Report) and Globus Medical (GMED - Free Report) .
AngioDynamics, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 38.2% for 2025. You can seethe complete list of today’s Zacks #1 Rank stocks here.
ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 19.2% year to date against the industry’s 6.1% growth.
Avanos, sporting a Zacks Rank of 1 at present, has an estimated growth rate of 31.2% for 2025. AVNS’ earnings surpassed estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 5.7%.
Avanos’ shares have risen 5.3% year to date compared with the industry’s 5.1% growth.
Globus Medical, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 38.7% year to date compared with the industry’s 6.1% growth.